In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Cetrorelix | Synthetic analog Triptorelin (Trelstar, Decapeptyl) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 486 | 1,338 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 57 (55 in people) | 164 (160 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 95 · 8 active45 more mention it but do not test it | 207 · 44 active104 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
The FDA label for Cetrotide says: “Prevention of premature LH surges during controlled ovarian stimulation”
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Cetrorelix | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual health | 357334212 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Trelstar says: “Treatment of advanced prostate cancer”
| Adverse eventsWhole body | 5353 | 105105 |
|---|
| Bone and jointImmune and inflammation | 77 | 74713 |
|---|
| Tumor growthReproductive and sexual health | 9612 | 524624 |
|---|
| Receptor activity and mechanismPharmacology | 224135 | 7425715 |
|---|
| PharmacokineticsPharmacology | 1111 | 19136 |
|---|
| LipidsMetabolic and weight | 55 | 981 |
|---|
| Urinary continence and bladder functionKidney and urinary | 33 | 55 |
|---|
| Inflammation markersKidney and urinary | 761 | 11 |
|---|
| Sexual functionReproductive and sexual health | 11 | 761 |
|---|
| Metabolic pathways and metabolomicsMetabolic and weight | 11 | 11 |
|---|
| Immune responseImmune and inflammation | 11 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Cetrorelix differs from Gonadorelin at 5 positions.
What is different
Triptorelin (Trelstar, Decapeptyl) differs from Gonadorelin at 2 positions and carries 1 added group.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
| Outcome | Cetrorelix | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Sex hormones and fertilityReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 27.6% Clinical pregnancy rate Dose studied: 0.25 mg/dayn = 4272016 | 22.7% Pregnancy rate Placebo: 22.1% Dose studied: 0.1 mgSingle injectionn = 3442010 |
| Tumor growthCancerCompared as: value in the arm that got the peptide, in % | −15.6% Mean uterine volume reduction, day 29 · Shown as a change. The study reports a mean uterine volume reduction, day 29 of this size. · cetrorelix 4 x 5 mg (SD 20.2) Placebo (SD 32.1): −5.1% Dose studied: 5 mg on days 1, 8, 15 and 224 weeksn not reported2007 | |
| Adverse eventsReproductive and sexual healthCompared as: value in the arm that got the peptide, in % | 1.6% Patients not given hCG for threatening OHSS n = 2732000 | 7.5% Cancellation for OHSS risk |
27.6%
Clinical pregnancy rate
Dose studied: 0.25 mg/dayn = 4272016
22.7%
Pregnancy rate
Placebo: 22.1%
Dose studied: 0.1 mgSingle injectionn = 3442010
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Cetrorelix | Triptorelin (Trelstar, Decapeptyl) |
|---|---|---|
| Bone and jointEndocrine and hormonesCompared as: value in the arm that got the peptide, in points | −0.82 points DAS28-CRP reduction · Shown as a change. The study reports a das28-crp reduction of this size. Placebo: −0.57 points Dose studied: 5 mg/day on days 1 and 2; 3 mg/day on days 3-5n = 992014 |
21 to 97% Nodule volume reduction Dose studied: 3.75 mg every 28 days, four administrationsn = 252007 |
−15.6%
Mean uterine volume reduction, day 29 · Shown as a change. The study reports a mean uterine volume reduction, day 29 of this size. · cetrorelix 4 x 5 mg (SD 20.2)
Placebo (SD 32.1): −5.1%
Dose studied: 5 mg on days 1, 8, 15 and 224 weeksn not reported2007
21 to 97%
Nodule volume reduction
Dose studied: 3.75 mg every 28 days, four administrationsn = 252007
1.6%
Patients not given hCG for threatening OHSS
n = 2732000
7.5%
Cancellation for OHSS risk
n = 2332012
No comparable result 16 randomized-trial results measure it in another way or another unit. |
| Urinary continence and bladder functionKidney and urinaryCompared as: difference from placebo, in points | 4 points IPSS improvement beyond placebo Dose studied: 60 mg followed by 30 mg 2 weeks latern not reported2010 | No randomized trial result 5 results from other study designs. |
|---|
−0.82 points
DAS28-CRP reduction · Shown as a change. The study reports a das28-crp reduction of this size.
Placebo: −0.57 points
Dose studied: 5 mg/day on days 1 and 2; 3 mg/day on days 3-5n = 992014
No comparable result
16 randomized-trial results measure it in another way or another unit.
4 points
IPSS improvement beyond placebo
Dose studied: 60 mg followed by 30 mg 2 weeks latern not reported2010
No randomized trial result
5 results from other study designs.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 95 trials, ranked by phase, then posted results and enrollment: 1 completed · 2 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
AEterna Zentaris667 participantsMar 2007 to Dec 2009
Benign Prostatic Hypertrophy
Bart CJM Fauser617 participantsFeb 2009 to Oct 2012
In Vitro Fertilization · Intracytoplasmic Sperm Injection
AEterna Zentaris528 participantsMar 2008 to Aug 2009
Benign Prostatic Hypertrophy
45 more mention it but do not test it. They only measure it or name it in their text.
Top 3 of 207 trials, ranked by phase, then posted results and enrollment: 2 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
ETOP IBCSG Partners Foundation3,066 participants17 Dec 2003 to 6 Nov 2024
Estrogen Receptor Positive Breast Cancer · Progesterone Receptor Positive Tumor · Recurrent Breast Carcinoma · Stage IA Breast Cancer · Stage IB Breast Cancer · Stage IIA Breast Cancer · Stage IIB Breast Cancer · Stage IIIA Breast Cancer
ETOP IBCSG Partners Foundation2,672 participants3 Nov 2003 to 23 Oct 2024
Breast Cancer
Radiation Therapy Oncology Group1,792 participantsFeb 2008 to 12 Jul 2018 (primary)
Prostate Cancer
104 more mention it but do not test it. They only measure it or name it in their text.